
AstraZeneca reveals $50bn investment in US facilities
Trump's pharma tariffs haven't appeared yet, but AstraZeneca has joined several of its peers with big investments in US manufacturing and R&D.
Newsletters and Deep Dive digital magazine
Trump's pharma tariffs haven't appeared yet, but AstraZeneca has joined several of its peers with big investments in US manufacturing and R&D.
The FDA seems to have won its staring contest with Sarepta over shipments of Elevidys, as the company blinks and agrees to a pause from today.
The FDA has rounded out its senior leadership by naming biopharma industry executive George Tidmarsh to the role of CDER director.
Merck gets another quick return on its $3.9bn SpringWorks takeover with EU approval of Ezmekly for tumours caused by neurofibromatosis type 1.
Sarepta has defied an FDA request to halt all use of its gene therapy for Duchenne muscular dystrophy, creating an intriguing regulatory impasse.
Editor's Picks
Newsletters and Deep Dive
digital magazine